Endothelial progenitor cells : a new real hope?
This book explores the role of endothelial progenitor cells (EPCs) in the context of regenerative medicine (RegMed). In particular, it reveals the value of RegMed as a new TM branch intended to improve the health and quality of life, by restoring, maintaining or enhancing tissue and functions of org...
Saved in:
| Main Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Cham :
Springer,
2017.
|
| Series: | UNIPA Springer series.
|
| Subjects: | |
| ISBN: | 9783319551074 9783319551067 |
| Physical Description: | 1 online resource (99 pages) |
Cover
Table of contents
| LEADER | 06921cam a2200493Mi 4500 | ||
|---|---|---|---|
| 001 | 97345 | ||
| 003 | CZ-ZlUTB | ||
| 005 | 20240914110516.0 | ||
| 006 | m o d | ||
| 007 | cr un|---aucuu | ||
| 008 | 170603s2017 sz ob 000 0 eng d | ||
| 040 | |a EBLCP |b eng |e pn |c EBLCP |d GW5XE |d N$T |d OCLCQ |d YDX |d AZU |d UAB |d UPM |d OCLCF |d COO |d OCLCO |d IOG |d OCLCO |d MERER |d ESU |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d JG0 |d OCLCO |d OCLCQ |d OCLCA |d OCLCQ |d OCLCO |d OCLCQ |d OCLCO |d U3W |d OCLCO |d CAUOI |d OCLCQ |d OCLCO |d KSU |d VT2 |d OCLCO |d AU@ |d WYU |d OCLCQ |d UKAHL |d OCLCQ |d OCLCO |d ERF |d ADU |d LEATE |d OCLCQ |d OCLCA |d OCLCQ | ||
| 020 | |a 9783319551074 |q (electronic bk.) | ||
| 020 | |z 9783319551067 |q (print) | ||
| 024 | 7 | |a 10.1007/978-3-319-55107-4 |2 doi | |
| 035 | |a (OCoLC)988870936 |z (OCoLC)988290875 |z (OCoLC)988389041 |z (OCoLC)990840760 |z (OCoLC)992508760 |z (OCoLC)992827910 |z (OCoLC)999519512 |z (OCoLC)1005800506 |z (OCoLC)1011795207 |z (OCoLC)1048116232 |z (OCoLC)1058374001 |z (OCoLC)1066461868 |z (OCoLC)1066621818 |z (OCoLC)1112526284 |z (OCoLC)1113455839 |z (OCoLC)1122814589 |z (OCoLC)1125814108 | ||
| 100 | 1 | |a Balistreri, Carmela Rita. | |
| 245 | 1 | 0 | |a Endothelial progenitor cells : |b a new real hope? / |c Carmela Rita Balistreri. |
| 260 | |a Cham : |b Springer, |c 2017. | ||
| 300 | |a 1 online resource (99 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a počítač |b c |2 rdamedia | ||
| 338 | |a online zdroj |b cr |2 rdacarrier | ||
| 490 | 1 | |a UNIPA Springer Series | |
| 505 | 0 | |a Preface; Acknowledgements; Contents; About the Author; Acronyms; 1 From Regenerative Medicine to Endothelial Progenitor Cells as Potential Candidates; Abstract; 1.1 Regenerative Medicine: A New Branch of Translational Medicine; 1.1.1 Stem Cell Therapy; 1.1.2 Stem Cells as Appropriate Candidates of Cell Therapy: Types of Stem Cell; 1.2 Endothelial Progenitor Cells: Other Emerging Candidates for RegMed Therapeutic Treatment; 1.2.1 Evidence of Several Circulating Subpopulations of EPCs; 1.2.2 EPCs: from BM progenitors to mature EC cells. | |
| 505 | 8 | |a 1.3 Phenotypic Markers and Levels of Circulating EPCs in Adult Subjects1.3.1 EPC Quantification Using Flow Cytometry and Its Limitation; 1.3.2 Factors Modulating EPC Quantitative and Qualitative Evaluation by Flow Cytometry; 1.3.3 Pathological or Physiological Conditions as Factors Able to Modulate EPC Quantitative and Qualitative Evaluation; 1.4 The Complex Process of Regulation of EPC Biology and Function: New Insights on the Key Role of Notch, ROS and Wnt Pathways and Their Crosstalk, and Epigenetics; 1.5 Conclusions; Acknowledgements; References. | |
| 505 | 8 | |a 2 Endothelial Progenitor Cells and Their Clinical Applications as Potential Disease Biomarkers and Therapeutic Agents: Evidence and Controversies Regarding Their EffectivenessAbstract; 2.1 Endothelial Dysfunction as the Early Event of Chronic Age-Related Diseases: EPCs as Cellular Biomarkers; 2.2 Relationship Between Circulating EPC Levels and Age-Related Diseases; 2.2.1 Unfavorable Factors Associated with Decreased Circulating EPC Levels; 2.2.2 Physiological Factors and High Circulating EPC Levels; 2.2.3 Exogenous Measures as Potential Strategies for Increasing Circulating EPC Levels. | |
| 505 | 8 | |a 2.3 Correlation Between Blood EPC Levels and Cardiovascular Profile2.3.1 Atherosclerosis; 2.3.2 Hypertension; 2.3.3 Coronary Artery Disease (CAD); 2.3.4 Bicuspid Aortic Valve, Aortic Valve Regurgitation (AR) and Aneurysm; 2.3.5 Cerebral Ischemia; 2.3.6 Other CVD Diseases; 2.4 EPCs in Alzheimer Disease; 2.5 Diabetes and EPCs; 2.6 EPCs in Solid and Hematological Cancers, and Recent Controversies Relating to Their Incorporation into Tumor Neovessels; 2.7 EPCs as Therapeutic Agents; 2.7.1 EPCs as Therapeutic Agents for CVDs: Focus on Ischemic Disease Treatment, Capacity and Doubts. | |
| 505 | 8 | |a 2.7.2 The Clinical Results and Indications of Autologous Therapies2.8 EPCs as Therapeutic Agents for Cancer: Focus on Anti-VEGF Treatments and Controversies in Their Efficacy; 2.9 EPCs as Therapeutic Agents for Alzheimer's Disease; 2.10 EPCs as Therapeutic Agents for Diabetes; 2.11 Controversies About EPC Use as Optimal Candidates for Cell Therapy; 2.12 Conclusions and Perspectives; References; 3 Endothelial Progenitor Cells: A Real Hope or an Unrealizable Dream? Which Measures or Strategies Are Necessary for making EPCs a clinical reality? Focus on a Potential Roadmap; Abstract. | |
| 500 | |a 3.1 EPCs: A Real Hope or a Unrealizable Dream? | ||
| 504 | |a Includes bibliographical references. | ||
| 506 | |a Plný text je dostupný pouze z IP adres počítačů Univerzity Tomáše Bati ve Zlíně nebo vzdáleným přístupem pro zaměstnance a studenty | ||
| 520 | |a This book explores the role of endothelial progenitor cells (EPCs) in the context of regenerative medicine (RegMed). In particular, it reveals the value of RegMed as a new TM branch intended to improve the health and quality of life, by restoring, maintaining or enhancing tissue and functions of organs. The book is divided into three chapters, the first of which describes the relevance of translational medicine (TM) as a new research approach to counteract the imposing challengeof age-related diseases. Of the diverse RegMed approaches, particular attention is paid to stem/progenitor cell-based therapies, their benefits and shortcomings, as well as to the description of types of stem and progenitor cells considered for regenerative cell therapies, such as EPCs as emerging candidates for RegMed applications. In turn, the second chapter outlines the clinical relevance of EPCs as both potential predictors, diagnostic and prognostic biomarkers of age-related diseases and therapeutic agents, discussing their advantages, disadvantages, and conflicting data. Chapter three proposes a potential roadmap for revising the findings and creating a clearer picture of valid data, which can provide support for various important aspects, i.e.isolating and characterizing EPCs by establishing standardized criteria for EPC research, identifying appropriate sub-populations for cell therapy, timing, dosing, priming of cells, and defining delivery modes for different applications. The book concludes with an overview of innovative strategies that could improve the efficacy of cell therapy at all levels, including cell priming, bio-nanotechnology, and tissue engineering. | ||
| 590 | |a SpringerLink |b Springer Complete eBooks | ||
| 650 | 0 | |a Stem cells. | |
| 650 | 0 | |a Endothelial cells. | |
| 655 | 7 | |a elektronické knihy |7 fd186907 |2 czenas | |
| 655 | 9 | |a electronic books |2 eczenas | |
| 776 | 0 | 8 | |i Print version: |a Balistreri, Carmela Rita. |t Endothelial Progenitor Cells : A New Real Hope? |d Cham : Springer International Publishing, ©2017 |z 9783319551067 |
| 830 | 0 | |a UNIPA Springer series. | |
| 856 | 4 | 0 | |u https://proxy.k.utb.cz/login?url=https://link.springer.com/10.1007/978-3-319-55107-4 |y Plný text |
| 992 | |c NTK-SpringerBLS | ||
| 999 | |c 97345 |d 97345 | ||
| 993 | |x NEPOSILAT |y EIZ | ||
Save to List
Cite this
Export Record
Email this